The Bacillary Dysentery (Shigellosis) drugs in development market research report provides comprehensive information on the therapeutics under development for Bacillary Dysentery (Shigellosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Bacillary Dysentery (Shigellosis). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Bacillary Dysentery (Shigellosis) and features dormant and discontinued products.
GlobalData tracks 28 drugs in development for Bacillary Dysentery (Shigellosis) by 20 companies/universities/institutes. The top development phase for Bacillary Dysentery (Shigellosis) is preclinical with 16 drugs in that stage. The Bacillary Dysentery (Shigellosis) pipeline has 20 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Bacillary Dysentery (Shigellosis) pipeline products market are: Immuron, Pasteur Institute and GSK.
The key targets in the Bacillary Dysentery (Shigellosis) pipeline products market include Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10), Shigella Invasin IpaB (62 kDa Antigen or ipaB), and Lipopolysaccharide (Endotoxin).
The key mechanisms of action in the Bacillary Dysentery (Shigellosis) pipeline product include Lipopolysaccharide (Endotoxin) Inhibitor with one drug in Preclinical. The Bacillary Dysentery (Shigellosis) pipeline products include four routes of administration with the top ROA being Oral and nine key molecule types in the Bacillary Dysentery (Shigellosis) pipeline products market including Conjugate Vaccine, and Subunit Vaccine.
Bacillary Dysentery (Shigellosis) overview
Shigella infection (shigellosis) is an intestinal disease caused by bacteria known as shigella. Symptoms include diarrhea, abdominal cramps, and fever. Predisposing factors include eating contaminated food, age, international travel, and being a homosexual man. Treatment includes antibiotics.
For a complete picture of Bacillary Dysentery (Shigellosis)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
